Tags : ES-SCLC

Merck & Co Reports Results of Keytruda in P-III KEYNOTE-604

Vartika Singh January 7, 2020

Shots: The P-III KEYNOTE-604 study involves assessing of Keytruda (pembrolizumab, 200 mg) + etoposide + Pt CT vs PBO + etoposide +PT CT in 453 patients newly diagnosed with ES-SCLC […]readmore

Pharma

Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage

Vartika Singh August 13, 2019

Shots: The approval is based on P-III IMpower133 study results assessing Tecentriq + carboplatin and etoposide vs carboplatin and etoposide monothx in 403 adults with chemotherapy-naïve ES-SCLC P-III IMpower133 study […]readmore

Tags : ES-SCLC

Merck & Co Reports Results of Keytruda in P-III KEYNOTE-604

Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ES-SCLC

Merck & Co Reports Results of Keytruda in P-III KEYNOTE-604

Roche’s Tecentriq (atezolizumab) Receives Health Canada’s Approval for 1L Extensive-Stage

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company